Dr Reddy’s Inks Pact With Gilead Sciences For Remdesivir
An employee operates machinery to arrange capsules for packaging at a pharmaceutical plant in Goa, India. (Photographer: Dhiraj Singh/Bloomberg)

Dr Reddy’s Inks Pact With Gilead Sciences For Remdesivir


Dr. Reddy's Laboratories Ltd., on Saturday announced it has entered into a non-exclusive licensing agreement with Gilead Sciences Inc. that will grant the drug maker the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this drug while it needs to do the manufacturing scale-up and obtain regulatory approval for marketing of this drug in the respective countries, a press release from the company said.

Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization by the U.S. FDA to treat hospitalised patients with severe Covid-19 illness.

Also read: Gilead’s Remdesivir Mainly Helped Healthier Covid-19 Patients

India currently does not manufacture Remdesivir.

The four companies - Hetero, Jubilant Life Sciences Ltd., Cipla Ltd. and Mylan NV - with which Gilead Sciences earlier entered into non-exclusive licensing agreements are still awaiting permission from the Drug Controller General of India for manufacturing and distribution of Remdesivir in the country.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.